Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but ...
Edwards pushes CMS to expand Medicare TAVR coverage to asymptomatic patients, sparking controversy among physicians over ...
The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
Medical Device Network on MSN
Edwards’ JenaValve acquisition nixed as FTC injunction approved by court
The FTC sued Edwards in August 2025, citing competition concerns in the nascent TAVR-AR market amid a potential deal for JenaValve.
Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results